Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Altimmune, Inc. (ALT)

Core Viewpoint - A securities class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, leading to significant stock price decline [1][2][4]. Group 1: Allegations and Trial Results - The lawsuit claims that Altimmune executives provided overly positive statements while concealing adverse facts about the trial results [2]. - The press release announcing the trial results was titled positively, despite one of the primary endpoints not achieving statistical significance [2][3]. - The trial showed a positive trend in fibrosis improvement, but the statistical significance was not met due to a higher-than-expected placebo response [3]. Group 2: Market Reaction - Following the announcement of the trial results, Altimmune's stock price fell from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [4]. Group 3: Legal Proceedings - Investors who purchased shares of Altimmune during the class period are encouraged to contact the law firm representing the class action before the lead plaintiff motion deadline on October 6, 2025 [5].